MedPath

A prospective cohort study in the development of type 2 diabetes and cardiovascular disease: The CODAM study

Conditions
diabetes and cardiovascular disease
10019280
10012653
10018424
Registration Number
NL-OMON37934
Lead Sponsor
niversiteit Maastricht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
500
Inclusion Criteria

Partricipant in baseline measurement of the CODAM study (MEC99-112)

Exclusion Criteria

None, except for limitations that interfere with any of the procedured to obtain informed consent according to the Helsinki declaration

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>(1) Development and progression of insulin resistance, glucose intolerance and<br /><br>type 2 diabetes in the CODAM study population.<br /><br>(2) Development and progression of atherosclerosis, vascular dysfunction and<br /><br>CVD in the CODAM study population.<br /><br><br /><br>Specific outcomes:<br /><br>- International Classification of Diseases version 10 (ICD-10 codes) :<br /><br>E11 (type 2 diabetes)<br /><br>I10-15 (hypertensive disease)<br /><br>I20-25 (ischaemic heart disease)<br /><br>- Subcutaneous and visceral fat<br /><br>- Ectopic fat in the liver<br /><br>- insulin resistance and glucose tolreance status<br /><br>- Measures of arterial structure (including carotid Intima-Media-Thikcness &<br /><br>Ankle-Brachial Index) and function (including arterial stiffness)<br /><br>- Presence of Metabolic Syndrome (according to the most recent defintion of<br /><br>Alberti et al (2009)) </p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath